Dr. Zongping Wang 王宗平
Chief Physician
Surgical Oncology, Zhejiang Cancer Hospital, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Early diagnosis of urological and male genital tumors. Laparoscopic and robotic surgery for prostate, kidney, bladder, and adrenal tumors, including organ-preserving treatments. Comprehensive management of advanced urological cancers.
Dr. Wang is Deputy Director of Urology and holds a medical doctorate from Peking Union Medical College. The doctor specializes in surgical and comprehensive treatment of urological tumors. Dr. Wang received the Best Surgical Video Award at the China Anti-Cancer Association annual meetings in 2017 and 2020.
Professional roles
- Member, Urological Tumor Professional Committee, China Anti-Cancer Association
- Member, Integrated Rehabilitation Professional Committee for Urogenital Tumors, China Anti-Cancer Association
- Member, Urology Branch, Zhejiang Medical Doctor Association
- Member, Robotic Surgery Professional Committee, Zhejiang Medical Doctor Association
Name order: in Chinese the family name comes first (Wang Zongping). Papers usually list the name as Zongping Wang or Wang Z.
Selected publications
27 papers on PubMed matched by name and affiliation; 6 as first or senior author since 2016. Most recent first- or senior-author papers:
- Int J Surg, 2025 (senior author): A nomogram for predicting lymph node metastases in nonmetastatic muscle-invasive bladder cancer: a SEER-based investigation. PubMed 39774955
- FASEB J, 2024 (senior author): Artesunate remarkably alleviates interstitial cystitis/bladder pain syndrome in a murine model: Novel molecular signature deciphered by bulk tissue and single-cell transcriptomic analysis. PubMed 39620925
- Biomol Biomed, 2024 (senior author): Urinary ATP may be a biomarker of interstitial cystitis/bladder pain syndrome and its severity. PubMed 37819233
- Front Public Health, 2022 (first author): Burden of kidney cancer and attributed risk factors in China from 1990 to 2019. PubMed 36589951
- Front Oncol, 2022 (senior author): PSMD2 promotes the progression of bladder cancer and is correlated with immune infiltration. PubMed 36505799
- Front Oncol, 2022 (first author): Editorial: Long-non coding RNAs in renal cell carcinoma. PubMed 36052231
- Int J Clin Exp Pathol, 2015 (first author): Interleukin-16 rs4778889 polymorphism contributes to the development of renal cell cancer in a Chinese population. PubMed 26823871
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion